Neoadjuvant immunotherapy produces event-free survival advantage over adjuvant therapy for patients with surgically resectable macroscopic stage IIIB/C/D melanoma. Pathologic response, determined as % residual viable tumor (%RVT), provides critical prognostic information and informs management decisions. Here, we assessed accuracy of %RVT calculation when reduced tumor bed (TB) was examined and leverage these results proposing streamlined protocols for pathological examination.
Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma.
Annals of Oncology | | R.V. Rawson, N.G. Maher, A.M. Menzies, S.N. Lo, N.Mesbah Ardakani, L.A. Jackett, I.A. Vergara, T.E. Pennington, K.F. Shannon, S. Ch’ng, M. Gonzalez, E.M. Burton, M.W. Lucas, I.L.M. Reijers, E.A. Rozeman, D.E. Gyorki, S. Sandhu, M.S. Carlino, J. Howle, M. Khattak, A. Van der Westhuizen, M.C. Andrews, V. Atkinson, A.C.J van Akkooi, A.J. Spillane, R.P.M Saw, B.A. van de Wiel, C.U. Blank, G.V. Long, M.T. Tetzlaff, R.A. Scolyer
Topics: skin-cancer, blood-cancer, immunotherapy